Kairos Pharma (NYSEAMERICAN:KAPA) Shares Down 4.1% – Time to Sell?

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA)’s stock price traded down 4.1% on Wednesday . The company traded as low as $0.3666 and last traded at $0.3681. 72,087 shares changed hands during trading, a decline of 42% from the average daily volume of 123,271 shares. The stock had previously closed at $0.3837.

Kairos Pharma Stock Performance

The business has a fifty day moving average of $0.49 and a 200-day moving average of $0.61. The company has a market capitalization of $7.88 million, a P/E ratio of -1.23 and a beta of 1.50.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter. Sell-side analysts anticipate that Kairos Pharma, Ltd. will post -0.37 EPS for the current year.

Institutional Investors Weigh In On Kairos Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd bought a new position in Kairos Pharma in the 2nd quarter valued at about $44,000. Two Sigma Investments LP acquired a new position in Kairos Pharma during the 3rd quarter valued at about $54,000. Finally, FNY Investment Advisers LLC bought a new stake in Kairos Pharma during the 3rd quarter worth approximately $27,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.